日本語View as Markdown

Molecular Hydrogen Effectively Heals Alkali-Injured Cornea via Suppression of Oxidative Stress.

アルカリ傷害角膜における分子状水素の酸化ストレス抑制を介した修復効果

animal study topical application positive

Abstract

This animal study investigated the effect of molecular hydrogen dissolved in phosphate-buffered saline (PBS) applied topically to rabbit corneas damaged by 0.25 M NaOH. Hydrogen solution was administered immediately after injury and continued for five days. Corneal transparency, which was lost following alkali exposure, was restored within ten days in the H2-treated group, and corneal hydration—measured by ultrasonic pachymetry—returned to physiological levels. In contrast, PBS-treated injured corneas showed persistent opacity and elevated hydration. At day 20 post-injury, H2-treated corneas exhibited markedly reduced expression of proinflammatory cytokines, nitrotyrosine residues (a marker of peroxynitrite), and malondialdehyde compared with PBS controls, where these markers remained elevated. The findings indicate that H2 solution promotes corneal recovery after alkali injury primarily through suppression of oxidative and nitrosative stress.

Mechanism

H2 solution reduces peroxynitrite formation and lipid peroxidation (MDA), while suppressing proinflammatory cytokine expression, thereby facilitating corneal tissue recovery following alkali-induced damage.

Bibliographic

Authors
Cejka C, Kossl J, Hermankova B, Holan V, Cejkova J
Journal
Oxid Med Cell Longev
Year
2017
PMID
28400915
DOI
10.1155/2017/8906027
PMC
PMC5376456

Tags

Disease:皮膚疾患 創傷治癒 Delivery:局所投与 Mechanism:炎症抑制 脂質過酸化 酸化ストレス ペルオキシナイトライト消去 活性酸素種

Delivery context

Topical applications have localized-effect reports, but systemic hydrogen intake is most efficient via inhalation. Inhalation carries explosion risk (empirical LFL of 10%; high-concentration devices are not recommended).

Safety notes

Topical applications have localized-effect reports, but systemic hydrogen intake is most efficient via inhalation. Inhalation carries explosion risk (empirical LFL of 10%; high-concentration devices are not recommended).

See also:

Other papers on the same disease / condition

Cite as: H2 Papers — PMID 28400915. https://h2-papers.org/en/papers/28400915
Source: PubMed PMID 28400915